Phillips-Medisize, a Molex company, is expanding the Molex Little Rock, Arkansas facility for an undisclosed fast-growing medical customer that provides consumable diagnostics cancer testing, with its take-home diagnostic kit.
The expansion will double production, as the device is currently being produced in the Phillips-Medisize New Richmond facility.
A second set of moulding and dedicated automation machines to package and assemble the device will installed for the expanded production footprint in Little Rock. The company annonced back in December that construction of purpose-built cleanroom suites, as well as FDA registration and ISO 13485 certification are scheduled to be complete by the second quarter of 2018.
Phillips-Medisize will mould, assemble with high speed automation, package and label the patient-ready device in the newly registered FDA facility, with production expected to begin in Q2 2018. This product will also include reagent handling and require unique device identification (UDI). Phillips-Medisize will use the number of the highly trained and qualified staff that already exists in the Little Rock operation.
The Little Rock facility establishes a new manufacturing site for Phillips-Medisize’s medical business with capabilities for filling, drug handling, electronics and connected devices. This investment aims to combine the innovative solutions and knowledge of Molex’s existing high volume automated electronics production operations with Phillips-Medisize’s proven platform of drug delivery and medical device expertise.
Matt Jennings, CEO and President of Phillips-Medisize said: “We are looking forward to expanding production with our customer and partnering with the Molex Little Rock team on this programme. The team provides decades of experience in moulding and assembly operations, cutting edge automation and quality control technology, as well as instant access to a team of highly talented and knowledgeable employees. We believe that Little Rock is the right location for our customer and will support both of our ambitious growth plans.”
Phillips-Medisize, a global outsource provider of design and manufacturing services to the drug delivery, diagnostics, medical device, and markets, was acquired in 2016 by Molex, whose parent company is Koch Industries.